Interim FX-322 Phase 2a Results Show Four Injection Schedule Had No Discernible Hearing Benefit
Separate FX-322 Phase 1b Study Confirms Hearing Improvement from Single Injection
Conference call at 8:30am ET today
Webcast details can be found on the Frequency Therapeutics’ investor relations site at https://investors.frequencytx.com/events-and-presentations, or by clicking here to enter the webcast directly.
https://finance.yahoo.com/news/frequency-therapeutics-releases-data-two-110000818.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.